Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022
Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third quarter of 2022
Read more at globenewswire.comAll information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here
Initiated Phase 1 clinical trial for KIN-3248 in the first quarter of 2022
Initial monotherapy data from the ongoing KN-8701 Phase 1 trial expected in the third quarter of 2022
Read more at globenewswire.com